404 related articles for article (PubMed ID: 28588093)
1. Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications.
Orgeron GM; James CA; Te Riele A; Tichnell C; Murray B; Bhonsale A; Kamel IR; Zimmerman SL; Judge DP; Crosson J; Tandri H; Calkins H
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28588093
[TBL] [Abstract][Full Text] [Related]
2. Competing risks of monomorphic vs. non-monomorphic ventricular arrhythmias in primary prevention implantable cardioverter-defibrillator recipients: Global Electrical Heterogeneity and Clinical Outcomes (GEHCO) study.
Tereshchenko LG; Waks JW; Tompkins C; Rogers AJ; Ehdaie A; Henrikson CA; Dalouk K; Raitt M; Kewalramani S; Kattan MW; Santangeli P; Wilkoff BW; Kapadia SR; Narayan SM; Chugh SS
Europace; 2024 Jun; 26(6):. PubMed ID: 38703375
[TBL] [Abstract][Full Text] [Related]
3. Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network.
Greenlee RT; Go AS; Peterson PN; Cassidy-Bushrow AE; Gaber C; Garcia-Montilla R; Glenn KA; Gupta N; Gurwitz JH; Hammill SC; Hayes JJ; Kadish A; Magid DJ; McManus DD; Multerer D; Powers JD; Reifler LM; Reynolds K; Schuger C; Sharma PP; Smith DH; Suits M; Sung SH; Varosy PD; Vidaillet HJ; Masoudi FA
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29581222
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and therapeutic strategies for arrhythmogenic right ventricular dysplasia/cardiomyopathy patient.
Wang W; James CA; Calkins H
Europace; 2019 Jan; 21(1):9-21. PubMed ID: 29688316
[TBL] [Abstract][Full Text] [Related]
5. Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe.
Carrick RT; De Marco C; Gasperetti A; Bosman LP; Gourraud JB; Trancuccio A; Mazzanti A; Murray B; Pendleton C; Tichnell C; Tandri H; Zeppenfeld K; Wilde AAM; Davies B; Seifer C; Roberts JD; Healey JS; MacIntyre C; Alqarawi W; Tadros R; Cutler MJ; Targetti M; Calò L; Vitali F; Bertini M; Compagnucci P; Casella M; Dello Russo A; Cappelletto C; De Luca A; Stolfo D; Duru F; Jensen HK; Svensson A; Dahlberg P; Hasselberg NE; Di Marco A; Jordà P; Arbelo E; Moreno Weidmann Z; Borowiec K; Delinière A; Biernacka EK; van Tintelen JP; Platonov PG; Olivotto I; Saguner AM; Haugaa KH; Cox M; Tondo C; Merlo M; Krahn AD; Te Riele ASJM; Wu KC; Calkins H; James CA; Cadrin-Tourigny J
Eur Heart J; 2024 Feb; 45(7):538-548. PubMed ID: 38195003
[TBL] [Abstract][Full Text] [Related]
6. Association of device detected atrial and ventricular tachyarrhythmia with adverse events in patients with an implantable cardioverter-defibrillator.
Abbas H; Younis A; Goldenberg I; McNitt S; Aktas MK; Tabaja C; Ojo A
J Cardiovasc Electrophysiol; 2024 Jun; 35(6):1203-1211. PubMed ID: 38606650
[TBL] [Abstract][Full Text] [Related]
7. Application and comparison of the FADES, MADIT, and SHFM-D risk models for risk stratification of prophylactic implantable cardioverter-defibrillator treatment.
van der Heijden AC; van Rees JB; Levy WC; van der Bom JG; Cannegieter SC; de Bie MK; van Erven L; Schalij MJ; Borleffs CJ
Europace; 2017 Jan; 19(1):72-80. PubMed ID: 28130376
[TBL] [Abstract][Full Text] [Related]
8. Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy.
Bosman LP; Nielsen Gerlach CL; Cadrin-Tourigny J; Orgeron G; Tichnell C; Murray B; Bourfiss M; van der Heijden JF; Yap SC; Zeppenfeld K; van den Berg MP; Wilde AAM; Asselbergs FW; Tandri H; Calkins H; van Tintelen JP; James CA; Te Riele ASJM
Europace; 2022 Feb; 24(2):296-305. PubMed ID: 34468736
[TBL] [Abstract][Full Text] [Related]
9. Arrhythmic risk stratification in arrhythmogenic right ventricular cardiomyopathy.
Gasperetti A; James CA; Carrick RT; Protonotarios A; Te Riele ASJM; Cadrin-Tourigny J; Compagnucci P; Duru F; van Tintelen P; Elliot PM; Calkins H
Europace; 2023 Nov; 25(11):. PubMed ID: 37935403
[TBL] [Abstract][Full Text] [Related]
10. Differences in underlying cardiac substrate among S-ICD recipients and its impact on long-term device-related outcomes: Real-world insights from the iSUSI registry.
Gasperetti A; Schiavone M; Milstein J; Compagnucci P; Vogler J; Laredo M; Breitenstein A; Gulletta S; Martinek M; Casella M; Kaiser L; Santini L; Rovaris G; Curnis A; Biffi M; Kuschyk J; Di Biase L; Tilz R; Tondo C; Forleo GB;
Heart Rhythm; 2024 Apr; 21(4):410-418. PubMed ID: 38246594
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
Kusumoto FM; Bailey KR; Chaouki AS; Deshmukh AJ; Gautam S; Kim RJ; Kramer DB; Lambrakos LK; Nasser NH; Sorajja D
Circulation; 2018 Sep; 138(13):e392-e414. PubMed ID: 29084732
[TBL] [Abstract][Full Text] [Related]
12. Electrical storm in a middle-aged man.
Ahadzi D; Agyekum F; Doku A; Yakubu AS; Hoedofia G; Ayetey H
Ghana Med J; 2023 Jun; 57(2):156-160. PubMed ID: 38504757
[TBL] [Abstract][Full Text] [Related]
13. Microvolt T-wave alternans complemented with electrophysiologic study for prediction of ventricular tachyarrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy: a long-term follow-up study.
Xue SL; Hou XF; Sun KY; Wang Y; Qian ZY; Wang QP; Shen SP; Yin HL; Zhang R; Yin HP; Zou JG
Chin Med J (Engl); 2019 Jun; 132(12):1406-1413. PubMed ID: 31205097
[TBL] [Abstract][Full Text] [Related]
14. Sex differences in outcomes of primary prevention implantable cardioverter-defibrillator therapy: combined registry data from eleven European countries.
Sticherling C; Arendacka B; Svendsen JH; Wijers S; Friede T; Stockinger J; Dommasch M; Merkely B; Willems R; Lubinski A; Scharfe M; Braunschweig F; Svetlosak M; Zürn CS; Huikuri H; Flevari P; Lund-Andersen C; Schaer BA; Tuinenburg AE; Bergau L; Schmidt G; Szeplaki G; Vandenberk B; Kowalczyk E; Eick C; Juntilla J; Conen D; Zabel M;
Europace; 2018 Jun; 20(6):963-970. PubMed ID: 29016784
[TBL] [Abstract][Full Text] [Related]
15. Arrhythmogenic right ventricular cardiomyopathy (ARVC): cardiovascular magnetic resonance update.
te Riele AS; Tandri H; Bluemke DA
J Cardiovasc Magn Reson; 2014 Jul; 16(1):50. PubMed ID: 25191878
[TBL] [Abstract][Full Text] [Related]
16. The pivotal role of compelling high-risk electrocardiographic markers in prediction of ventricular arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: A systematic review and meta-analysis.
Iqbal M; Kamarullah W; Achmad C; Karwiky G; Akbar MR
Curr Probl Cardiol; 2024 Feb; 49(2):102241. PubMed ID: 38040211
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation in atrial fibrillation and implantable cardioverter defibrillator implantation in arrhythmogenic right ventricular cardiomyopathy: need for improving patient selection.
Crea F
Eur Heart J; 2024 Feb; 45(7):491-494. PubMed ID: 38366819
[No Abstract] [Full Text] [Related]
18. Transatlantic differences in the use of implantable cardioverter defibrillators in arrhythmogenic right ventricular cardiomyopathy.
Elliott PM
Eur Heart J; 2024 Feb; 45(7):549-551. PubMed ID: 38289329
[No Abstract] [Full Text] [Related]
19. Diagnostic pitfalls in patients referred for arrhythmogenic right ventricular cardiomyopathy.
Sampognaro JR; Gaine SP; Sharma A; Tichnell C; Murray B; Shaik Z; Zimmerman SL; James CA; Gasperetti A; Calkins H
Heart Rhythm; 2023 Dec; 20(12):1720-1726. PubMed ID: 37657721
[TBL] [Abstract][Full Text] [Related]
20. Management of arrhythmogenic right ventricular cardiomyopathy.
Al-Aidarous S; Protonotarios A; Elliott PM; Lambiase PD
Heart; 2024 Jan; 110(3):156-162. PubMed ID: 37433658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
